Business Context and Reporting Period
This Form 8-K Current Report was filed by AcelRx Pharmaceuticals, Inc. (ACRX) on December 10, 2020, regarding events occurring on December 9, 2020. The registrant is a Delaware corporation with principal executive offices in Redwood City, California, and its common stock trades on the Nasdaq Global Market.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance metrics. Key figures include:
- Securities Issued: 8,333,333 shares of Common Stock.
- Offering Price: $1.20 per share.
- Gross Proceeds: Expected aggregate of $10 million.
- Underwriting: No underwriter or placement agent participated.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report.
Material Changes
The material change reported is the execution of a Securities Purchase Agreement with funds affiliated with three life sciences investors (existing and new). This transaction results in the issuance of new equity and an influx of capital, altering the company's capital structure and cash position upon closing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. The transaction was conducted pursuant to an effective registration statement on Form S-3 (No. 333-239156). The Purchase Agreement includes customary representations, warranties, conditions to closing, and indemnification obligations.
Investor Verification Checklist
- Verify the closing date and actual receipt of the $10 million gross proceeds.
- Confirm the identity of the three life science investor funds involved.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) for specific covenants or conditions.
- Check subsequent filings for the impact of this issuance on total outstanding shares and dilution.